| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
This compound is a biotinylation tool; the DBCO group reacts with azides, while the biotin group serves as a high-affinity tag for streptavidin or avidin. It does not target a biological receptor but is used for capture, purification, or detection of azide-labeled biomolecules. The sulfo group improves solubility and reduces non-specific binding.
|
|---|---|
| ln Vitro |
An ADC cytotoxin is connected to an antibody by use of an ADC linker to form an ADC.
In vitro, DBCO-Sulfo-Link-biotin is used to biotinylate azide-modified proteins, DNA, RNA, or glycans. The reaction is fast and specific. The biotinylated products can be detected by streptavidin-HRP or purified on streptavidin beads. The compound is often used in cell surface labeling, glycomics, and proteomics. |
| ln Vivo |
No in vivo activity is attributed to the compound itself; it may be used to biotinylate probes for in vivo imaging or targeting.
|
| Enzyme Assay |
No cell-free receptor binding assays are performed. The compound's reactivity is assessed by reaction with an azide-containing small molecule and analysis by LC-MS. Biotin incorporation is quantified by streptavidin binding assay.
|
| Cell Assay |
Cell-based assays involve incubating cells with azide-sugars (e.g., Ac4ManNAz) to label glycans, then treating with DBCO-Sulfo-Link-biotin to biotinylate cell surface glycans. Cells are then stained with fluorescent streptavidin and analyzed by flow cytometry or microscopy. The compound is used at 10-100 µM.
|
| Animal Protocol |
In vivo experiments are not performed with the free reagent; it may be used in pretargeted biotinylation strategies. For example, an azide-modified antibody is given first, then the biotin-DBCO probe is injected, followed by streptavidin-conjugated drug. No standard protocols exist.
|
| ADME/Pharmacokinetics |
Pharmacokinetics of the compound are not studied. It is highly soluble in water. The biotin moiety is stable.
|
| Toxicity/Toxicokinetics |
Toxicity data is not available. The compound is considered low-toxicity for in vitro use. Handle with standard precautions.
|
| References |
[1]. Portnoff AD, et al. An antidote approach to reduce risk and broaden utility of antibody-based therapeutics. J Biol Chem. 2017 May 19;292(20):8498-8506.
|
| Additional Infomation |
DBCO-Sulfo-Link-biotin is a sulfonated biotin-DBCO conjugate with molecular formula C35H44N6O9S2 (sodium salt) and molecular weight about 773. It is a white to off-white powder. It is a popular tool for bioorthogonal labeling of glycans and proteins. Available for research only.
|
| Molecular Formula |
C31H35N5O7S2
|
|---|---|
| Molecular Weight |
653.768904924393
|
| Exact Mass |
653.197
|
| CAS # |
1363444-70-5
|
| PubChem CID |
77078146
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
0.9
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
45
|
| Complexity |
1290
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C1[C@H]2[C@@H]([C@@H](S1)CCCCC(=O)NCC(C(=O)NCCC(=O)N3CC4=CC=CC=C4C#CC5=CC=CC=C53)S(=O)(=O)O)NC(=O)N2
|
| InChi Key |
XDEWKDCHVSWNBX-MXGHRJRVSA-N
|
| InChi Code |
InChI=1S/C31H35N5O7S2/c37-27(12-6-5-11-25-29-23(19-44-25)34-31(40)35-29)33-17-26(45(41,42)43)30(39)32-16-15-28(38)36-18-22-9-2-1-7-20(22)13-14-21-8-3-4-10-24(21)36/h1-4,7-10,23,25-26,29H,5-6,11-12,15-19H2,(H,32,39)(H,33,37)(H2,34,35,40)(H,41,42,43)/t23-,25-,26?,29-/m0/s1
|
| Chemical Name |
3-[5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-1-[[3-(2-azatricyclo[10.4.0.04,9]hexadeca-1(16),4,6,8,12,14-hexaen-10-yn-2-yl)-3-oxopropyl]amino]-1-oxopropane-2-sulfonic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5296 mL | 7.6479 mL | 15.2959 mL | |
| 5 mM | 0.3059 mL | 1.5296 mL | 3.0592 mL | |
| 10 mM | 0.1530 mL | 0.7648 mL | 1.5296 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
